{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/PFE/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-11-22T19:14:19.671Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":8278,"canonical_name":"PFIZER INC","cik":"0000078003","uei":null,"lei":null,"duns":null,"ticker":"PFE"},"window_days":180,"min_importance":60,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"clinical":30,"fda":3},"count":33,"timeline":[{"ts":"2026-11-12","kind":"clinical.trial","reporter":"Pfizer","title":"The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or Overweight","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07932925","excerpt":"[\"Urinary Incontinence, Stress\",\"Overweight and/or Obesity\"]","importance":60},{"ts":"2026-11-09","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B Without Inhibitors","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07923981","excerpt":"[\"Hemophilia A or B\"]","importance":60},{"ts":"2026-11-05","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07919678","excerpt":"[\"Obesity\",\"Overweight\",\"Osteoarthritis of the Knee\"]","importance":60},{"ts":"2026-11-04","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07915609","excerpt":"[\"Obesity\",\"Overweight and/or Obesity\",\"Knee Osteoarthritis\",\"Diabetes Melliuts, Type 2\"]","importance":60},{"ts":"2026-10-22","kind":"clinical.trial","reporter":"Pfizer","title":"A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07890597","excerpt":"[\"Early Breast Cancer\",\"Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-)\"]","importance":60},{"ts":"2026-10-21","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07885956","excerpt":"[\"Respiratory Syncytial Virus (RSV)\"]","importance":60},{"ts":"2026-10-19","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07881757","excerpt":"[\"Apnea\",\"Sleep Disorders\",\"Overweight and/or Obesity\"]","importance":60},{"ts":"2026-10-15","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07874633","excerpt":"[\"Obesity\",\"Overweight\"]","importance":60},{"ts":"2026-10-09","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07819097","excerpt":"[\"Adult\",\"Healthy Participants\"]","importance":60},{"ts":"2026-10-09","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07869043","excerpt":"[\"Asthma\"]","importance":60},{"ts":"2026-10-08","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07823608","excerpt":"[\"Apnea\",\"Sleep Disorders\",\"Overweight and/or Obesity\"]","importance":60},{"ts":"2026-10-06","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07772921","excerpt":"[\"Asthma\"]","importance":60},{"ts":"2026-10-06","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07783425","excerpt":"[\"Atopic Dermatitis\"]","importance":60},{"ts":"2026-09-29","kind":"fda.recall","reporter":"Pfizer","title":"Class II","security_title":"Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 100 tablet bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria.  NDC 60793-859-01.","excerpt":"Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.","accession_number":"D-0052-2027","status":"Ongoing","product_type":"drug","importance":60},{"ts":"2026-09-29","kind":"fda.recall","reporter":"Pfizer","title":"Class II","security_title":"Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 1000-count bottle, Rx only,  Distributed by Pfizer Inc., New York, NY 10017, Made in Austria.  NDC 60793-859-10","excerpt":"Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.","accession_number":"D-0051-2027","status":"Ongoing","product_type":"drug","importance":60},{"ts":"2026-09-29","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07845500","excerpt":"[\"Obesity\",\"Overweight and/or Obesity\",\"Overweight\",\"Treatment Of Obesity\"]","importance":60},{"ts":"2026-09-28","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07595549","excerpt":"[\"Obesity\",\"Overweight and/or Obesity\",\"Overweight\"]","importance":60},{"ts":"2026-09-25","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07729462","excerpt":"[\"Preventive Treatment of Migraine\"]","importance":60},{"ts":"2026-09-25","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07768345","excerpt":"[\"Respiratory Syncytial Virus (RSV)\"]","importance":60},{"ts":"2026-09-25","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07792954","excerpt":"[\"Obesity\",\"Overweight\"]","importance":60},{"ts":"2026-09-25","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07794774","excerpt":"[\"Obesity\"]","importance":60},{"ts":"2026-09-25","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07794761","excerpt":"[\"Obesity\"]","importance":60},{"ts":"2026-09-24","kind":"clinical.trial","reporter":"Pfizer","title":"A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07653100","excerpt":"[\"Respiratory Syncytial Virus (RSV)\"]","importance":60},{"ts":"2026-09-24","kind":"clinical.trial","reporter":"Pfizer","title":"Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07839871","excerpt":"[\"Respiratory Syncytial Virus (RSV)\"]","importance":60},{"ts":"2026-09-24","kind":"clinical.trial","reporter":"Pfizer","title":"A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of Time","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07839884","excerpt":"[\"Moderate to Severe Chronic Obstructive Pulmonary Disease\"]","importance":60},{"ts":"2026-09-23","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07794748","excerpt":"[\"Pneumococcal Disease\"]","importance":60},{"ts":"2026-09-16","kind":"clinical.trial","reporter":"Pfizer","title":"Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07823595","excerpt":"[\"Atopic Dermatitis\"]","importance":60},{"ts":"2026-09-10","kind":"clinical.trial","reporter":"Pfizer","title":"A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07733765","excerpt":"[\"Alopecia Areata\"]","importance":60},{"ts":"2026-09-08","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07629440","excerpt":"[\"Pneumococcal Disease\"]","importance":60},{"ts":"2026-09-04","kind":"fda.recall","reporter":"Pfizer","title":"Class II","security_title":"Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA, Vial NDC 0409-5820-11, Carton NDC 0409-5820-01.","excerpt":"Lack of Assurance of Sterility","accession_number":"D-0853-2026","status":"Ongoing","product_type":"drug","importance":60},{"ts":"2026-09-04","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07765888","excerpt":"[\"Atopic Dermatitis\"]","importance":60},{"ts":"2026-08-31","kind":"clinical.trial","reporter":"Pfizer","title":"Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07660198","excerpt":"[\"Pneumococcal Disease\"]","importance":60},{"ts":"2026-08-10","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Evaluate 20vPnC in Healthy Chinese Infants","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07754539","excerpt":"[\"Pneumococcal Diseases\"]","importance":60}]}